** Shares of Infinity Pharmaceuticals Inc fall ~43% to $0.12 premarket
** Co says it has terminated merger agreement with cancer therapy developer MEI Pharma Inc
** Says MEIP shareholders did not approve the merger with Infinity
** INFI says will explore strategic alternatives intended to realize the potential value of its lead drug candidate, eganelisib
** Eganelisib is being tested in a mid-stage study for a type of head and neck cancer -INFI
** INFI is entitled to reimbursement of certain expenses and fees of $1 mln from MEIP and also eligible to receive an additional $4 mln under the terms of the merger agreement - INFI
** Up to last close, INFI shares down ~60% this year
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。